Last month, Revance and Teoxane announced US Food and Drug Administration (FDA) approval of RHA Dynamic Volume for cheek augmentation and correction of age-related midface contour deficiencies in adults aged 22 years and older, as reported by Dermatology Times. Formerly known as RHA 4 Mepi, the product will be formally launched under its new name in the first quarter of 2026, expanding the clinical indications of the Teoxane RHA Collection in the US injectable aesthetics market.
The Filler Technology
RHA Dynamic Volume is designed to provide structural support and volumization while maintaining natural facial movement, addressing a key clinical challenge in midface rejuvenation. The filler is formulated to deliver durable volume and contour while adapting to dynamic facial expressions, a property attributed to its high dynamic strength, stretch, and capacity to preserve structural integrity over time. Central to these characteristics is Teoxane’s Preserved Network Technology (PNT), a proprietary, heat-free, homogenous crosslinking process that helps maintain the natural structure of hyaluronic acid. This manufacturing approach aims to support tissue integration and elasticity, allowing the filler to perform both at rest and during motion.
“The FDA approval of RHA Dynamic Volume for the midface is a meaningful step in the continued expansion of Revance’s portfolio and reflects our long-term investment in scientific innovation that moves aesthetic medicine forward. Designed to move seamlessly with facial animation, this formulation provides structural support when placed deeply while allowing for dynamic contouring and efficient product use when placed superficially in the midface. RHA Dynamic Volume advances what’s possible in facial aesthetics,” Conor Gallagher, PhD, chief scientific officer of Revance, said to Dermatology Times.
Supporting Research
The approval was supported by data from a robust 52-week phase 3 clinical trial program evaluating the efficacy and safety of RHA Dynamic Volume in patients with moderate to severe midface volume deficiency. The pivotal study was a prospective, randomized, multicenter, double-blinded, head-to-head comparison with Juvéderm Voluma XC. Results demonstrated that RHA Dynamic Volume achieved comparable effectiveness to the comparator product while requiring fewer treatment sessions and touch-ups to reach similar aesthetic outcomes.
Patient-reported outcomes further supported the clinical performance of RHA Dynamic Volume. Participants reported improvements in cheek attractiveness, youthfulness, smoothness, contour, and symmetry, with more than 94 percent indicating that results looked and felt natural both at rest and in motion for up to 1 year following treatment. Importantly, patients did not report a perception of restricted facial movement, reinforcing the product’s ability to adapt to dynamic facial expressions without compromising expressiveness.
Injection technique and treatment approach were also highlighted in the clinical program. Approximately 75 percent of subjects were treated in both superficial and deep fat compartments, reflecting a contemporary multilayer strategy for midface restoration. This approach aims to achieve balanced volumization and structural support while using the product efficiently. RHA Dynamic Volume demonstrated a favorable safety profile, with no late-onset or serious treatment-related adverse events and no events classified as granulomas or delayed inflammatory responses over the study period.
Expert Perspectives
Sandra Chennoufi, chief scientific officer of Teoxane, emphasized that the FDA approval brings to the US a midface contouring strategy that has been supported by more than a decade of post-marketing experience in Europe. “Leveraging the versatility of RHA Dynamic Volume and the Teoxane MLT Multilayering Technique, physicians can now address midface volume deficiencies by targeting multiple tissue depths for deep and superficial fat pads,” she said in a press release.
Collectively, this FDA approval of RHA Dynamic Volume expands the therapeutic toolkit for midface rejuvenation, offering dermatologists and aesthetic clinicians a filler option designed to balance durability, adaptability, and natural expression, supported by long-term clinical data and established international experience.
“As the modern aesthetic patient continues to evolve, we’re seeing increased demand for solutions that address midface volume loss associated with GLP-1 use, peri- and menopausal changes. This approval allows providers to meet those needs with a treatment option designed to deliver balanced support while preserving natural movement and expression at every stage of aging,” Adelle Walker, chief marketing officer of Revance, told Dermatology Times.
